Urinary Urgency
15
2
2
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
20.0%
3 terminated out of 15 trials
66.7%
-19.8% vs benchmark
33%
5 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (15)
Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer
FREEOAB Study for Overactive Bladder
Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections
Optimal Injection Interval for Intra-Detrusor Botulinum Toxin
Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders
OnabotulinumtoxinA Bladder Injection Study
Fluids Affecting Bladder Urgency and Lower Urinary Symptoms
Group Medical Visits for Latina Women With Urgency Urinary Incontinence
Efficacy and Safety of Gabapentin in Treating Overactive Bladder
Refractory Urge Incontinence and Botox Injections
Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)